Table 3. . Inverse probability treatment weighted all-cause and acute lymphoblastic leukemia-related costs during first relapse/refractory in the follow-up period.
| Cost category† | All-cause costs, PPPM, mean (SD) | ALL-related costs, PPPM, mean (SD) | ||
|---|---|---|---|---|
| InO (n = 29) | Blina (n = 23) | InO (n = 29) | Blina (n = 23) | |
| Total healthcare costs | 122,461 (104,348) | 176,306 (201,727) | 116,774 (105,327) | 171,093 (198,208) |
| Medical costs | 121,344 (104,549) | 175,788 (201,625) | 116,641 (105,388) | 171,093 (198,208) |
| Office visits | 9344 (21,313) | 3132 (11,312) | 11,646 (23,403) | 2898 (11,353) |
| Outpatient visits | 90,718 (105,269) | 69,459 (83,529) | 90,308 (106,078) | 71,071 (77,453) |
| Emergency room visits | 360 (439) | 264 (298) | –‡ | –‡ |
| Inpatient stays | 34,375 (51,849) | 110,364 (215,119) | 37,636 (54,316) | 110,364 (215,119) |
| ICU stays | 27,649 (53,552) | 22,582 (32,996) | 25,176 (47,625) | 5479 (15,652) |
| Other medical costs | 894 (3,764) | 19,589 (26,580) | 240 (836) | 19,483 (26,498) |
| Pharmacy costs | 1117 (1471) | 519 (774) | 133 (714) | 0 (0) |
Bolded numbers are statistically significant (p < 0.001).
†
Total costs calculated among all patients; costs for specific utilization categories calculated among patients with ≥1 claim for the specific utilization type. Costs were adjusted to 2020 US dollars using the Consumer Price Index.
‡
Values suppressed due to small sample size (<5 patients).
Blina: Blinatumomab; InO: Inotuzumab ozogamicin; ICU: Intensive care unit; PPPM: Per-patient-per-month; SD: Standard deviation.